NOT FOR REPRINT
Page Printed from: benefitspro.com/author/profile/c.j.-marwitz/?page=202
Sign In To follow
When looking at value versus growth stocks over longer periods of time, divergent patterns have emerged.
An epilepsy specialist calls the drug, which is based on the marijuana plant, a potential 'life-changer' for some.
The bulk of 401(k) cashout leakage results from a lack of plan-to-plan portability.
Direxion, a $13.6 billion money manager, is starting an ETF. Here's what you need to know.
Salesperson or subject matter expert: Which one are you?
This may be a once-in-a-lifetime occurrence. Unless Stanley's a boomerang employee.
Although every RFP is unique, depending on what plan sponsors are looking for, there are some big do's and don'ts.
There are three things many employees might want in a financial wellness program that sponsors and advisors should note.
Shares of drug-supply-chain stocks have been in a tizzy for months over what Amazon might do.
Here are some tips gleaned from a panel session on prospecting and marketing for advisors.